Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.

Abstract

The FDA approved bimatoprost ophthalmic solution 0.03% for treatment of eyelash hypotrichosis in 2008. Consumer concern persists regarding potential side effects of this product. To identify gaps in the safety information associated with the use of prostaglandin eyelash growth products. Literature searches were performed using PubMed, Embase, and Nexis Uni databases without restriction to publication date, language, or study setting. The literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. Study design choices create gaps in our understanding of the clinical safety of these products. Because of study design choice, clinical trials of bimatoprost for eyelash growth may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy. The risk of increased iris pigmentation remains inadequately investigated. Consequently, there is an ongoing need to educate and monitor patients who choose to use these products.